Louis BaseneseLouis Basenese

Louis Basenese is a professional investor, and one of the country’s leading technology analysts.

He’s spent the past 20 years analyzing emerging technologies, and developing a proven methodology to consistently profit from them.

Lou began his investment career at Morgan Stanley, where he was eventually tasked with directing over $1.5 billion in capital.

Based on his proven track record as a financial analyst and investor, Lou became a television commentator on Fox Business and CNBC, and a market expert in the pages of The Wall Street Journal and Business Insider. But ultimately, Lou found he preferred helping Main Street investors like you.

By providing ordinary investors with extraordinary research, he discovered that he can help his readers change their financial futures, and change their lives for the better. And that explains why he recently launched Trend Trader Daily.

With this new service, Lou can share his research with you on groundbreaking new technologies and emerging sectors — well before he shares this information with the general public on TV, the internet, or anywhere else.


10 Easy Ways to Find Top Biotech Stocks

Dear Wall Street Daily Reader, For the better part of 18 months now, I’ve been banging the table on biotech stocks — and it’s paid handsome dividends. But one reader recently challenged me on this… “It’s easy for you to say, ‘Buy biotech!’ and then find compelling biotech companies because you’re an analyst. It’s not...

Buy The Dip & Watch SPAC BOOM

Trend Trader Daily editor, Lou Basenese shares how investors can profit from the flashiest trend in finance. “A proper ‘investor first’ foundation has been laid for a massive SPAC boom. And make no mistake, we’re living in SPAC boom times right now…”

Keep Buying the Dips in These 3 Sectors

Trend Trader Daily editor, Lou Basenese shares his personal recommendations on buying the dip in three key sectors. “The market’s having a conniption right now as interest rates rise, stoking inflation concerns. But please don’t join in on the near-sighted panic!”

[Charts] Roasting Shorts and the Fake-Brain Boom

If you think the GameStop Corp. (GME) saga only involves a small handful of heavily-shorted stocks, think again… Pretty much every heavily-shorted stock in the Russell 3000 with a nose-bleed valuation is surging. But that does NOT mean a GME endorsement. So, where SHOULD you be investing? Glad you asked…

Don’t Buy Any Covid-19 Vaccine Stocks Until You Read This

With shares of Novavax, Inc. (NVAX) doubling during the last few weeks of January — and surging more than 3,000% over the last year — investors are on the lookout for the next Covid-19 vaccine stock set to soar. But it’s no easy task. There are currently 4,636 Covid-19 treatments and trials underway. Sorting through all those trials quickly enough to identify any actionable opportunities might seem like mission impossible. But, Trend Trader Daily editor and founder, Lou Basenese, is going to help you do exactly that.

Biotech Boom 2.0

Trend Trader Daily editor and founder, Lou Basenese, is back with his prediction on 2021’s top performer: biotech. “It’s now become vital to survival. Literally. And that’s not going to change anytime soon.” Read on to find out why, and how you can get in on the Biotech Boom 2.0.